肺巨噬细胞组成变化与COVID-19严重程度及康复相关
研究基于Mount Sinai COVID-19生物样本库近600例住院患者的纵向随访,分析免疫特征与疾病严重程度及生存的关系。重度和死亡患者表现为抗原呈递特征改变、炎性未成熟髓系细胞增多及滤泡外活化B细胞增加;重症患者肺组织驻留肺泡巨噬细胞严重耗竭且抗原呈递特征改变,并伴随炎性单核细胞和单核细胞来源巨噬细胞流入。肺泡巨噬细胞池大小与患者结局相关,康复患者其数量和功能恢复至稳态。
要点
- 中度疾病和生存与更强的抗原呈递及效应T细胞特征相关。
- 重症和死亡与抗原呈递特征改变、炎性未成熟髓系细胞增多及滤泡外活化B细胞相关。
- 重症患者肺泡巨噬细胞严重耗竭且抗原呈递特征改变,康复者其数量和功能恢复至稳态。
核心结论
- 局部和全身髓系细胞失调是COVID-19严重程度的驱动因素。
- 调节肺内肺泡巨噬细胞数量和活性可能是治疗危重炎性肺疾病的可行策略。
研究设计与样本
- 研究组建了Mount Sinai COVID-19生物样本库,纳入近600例住院患者,在2020年疫情高峰期间进行纵向随访。
主要发现
- 中度疾病和生存与更强的抗原呈递和效应T细胞特征相关。
- 重症和死亡与抗原呈递特征改变、炎性未成熟髓系细胞数量增加及滤泡外活化B细胞相关,后者此前与自身抗体形成相关。
- 重症COVID-19患者肺组织驻留肺泡巨噬细胞不仅严重耗竭,而且抗原呈递特征改变,同时伴随炎性单核细胞和单核细胞来源巨噬细胞流入。
- 肺泡巨噬细胞池的大小与患者结局相关,康复患者肺泡巨噬细胞数量和功能恢复至稳态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although it has been more than 2 years since the start of the coronavirus disease 2019 (COVID-19) pandemic, COVID-19 continues to be a worldwide health crisis. Despite the development of preventive vaccines, therapies to treat COVID-19 and other inflammatory diseases remain a major unmet need in medicine. Our study sought to identify drivers of disease severity and mortality to develop tailored immunotherapy strategies to halt disease progression. We assembled the Mount Sinai COVID-19 Biobank, which was composed of almost 600 hospitalized patients followed longitudinally through the peak of the pandemic in 2020. Moderate disease and survival were associated with a stronger antigen presentation and effector T cell signature. In contrast, severe disease and death were associated with an altered antigen presentation signature, increased numbers of inflammatory immature myeloid cells, and extrafollicular activated B cells that have been previously associated with autoantibody formation. In severely ill patients with COVID-19, lung tissue-resident alveolar macrophages not only were drastically depleted but also had an altered antigen presentation signature, which coincided with an influx of inflammatory monocytes and monocyte-derived macrophages. In addition, we found that the size of the alveolar macrophage pool correlated with patient outcome and that alveolar macrophage numbers and functionality were restored to homeostasis in patients who recovered from COVID-19. These data suggest that local and systemic myeloid cell dysregulation are drivers of COVID-19 severity and modulation of alveolar macrophage numbers and activity in the lung may be a viable therapeutic strategy for the treatment of critical inflammatory lung diseases.
引用
- Chen ST, Park MD, Del Valle DM, et al. A shift in lung macrophage composition is associated with COVID-19 severity and recovery. Sci Transl Med. 2022. PMID: 36103512. doi:10.1126/scitranslmed.abn5168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。